pentobarbital will minimize the extent or effect of elbasvir/grazoprevir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic result of elbasvir/grazoprevir could be decreased if coadministered with sturdy CYP3A inducers and is particularly consequently contraindicated.Parenteral options of barbiturates are hig